Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

Journal of Clinical Oncology

Volumn 22, Issue 1, 2004, Pages 77-85

  Soulieres, Denis ^a   Senzer, Neil N ^a   Vokes, Everett E ^a   Hidalgo, Manuel ^a   Agarvala, Sanjiv S ^a   Siu, Lillian L ^a  

^a NOTRE DAME HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB;

ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEAD AND NECK CANCER; HUMAN; METASTASIS; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; DIARRHEA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EXANTHEMA; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 1842772526     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.06.075     Document Type: Article

References (24)

1. Tannock IF: General principles of chemotherapy, in Million RR and Cassisi NJ (eds): Management of Head and Neck Cancer: A Multidisciplinary Approach (ed 2). Philadelphia, PA, J.B. Lippincott Company. 1994, pp143-156
2. Browman GP, Cronin L: Standard chemotherapy in squamous cell head and neck cancer: What we have learned from randomized trials. Semin Oncol 21:311-319, 1994
3. Forastiere AA, Leong T, Rowinsky E, et al: Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 19:1088-1095, 2001
4. Glisson BS, Murphy BA, Frenette G, et al: Phase Ii trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 20:1593-1599, 2002
5. Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-212, 1990
6. Carpenter G, Cohen S: Epidermal growth factor. J Biol Chem 265:7709-7712, 1990
7. Mendelson J, Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene 19:6550-6565, 2000
8. Harari PM, Huang S-M: Modulation of molecular targets to enhance radiation. Clin Cancer Res 6:323-325, 2000
9. Herbst RS, Langer CJ: Epidermal growth factor receptors as a target for cancer treatment: The emerging role of IMC-225 in the treatment of lung and head and neck cancers. Semin Oncol 29:27-36, 2002 (suppl 4)
10. Grandis JR, Tweardy DJ: Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53:3579-3584, 1993
11. Santini J, Formento J, Francoual M, et al: Characterization, quantification and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 13:132-139, 1991
12. Issing WJ, Liebich C, Wustrow TP, et al: Coexpression of epidermal growth factor receptor and TGF-alpha and survival in upper aerodigestive tract cancer. Anticancer Res 16:283-288, 1996
13. Grandis JR, Melhem MF, Gooding WE, et al: Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824-832, 1998
14. Pollack VA, Savage DM, Baker DA, et al: Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291:739-748, 1999
15. Hidalgo M, Siu LL, Nemunaitis J, et al: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279, 2001
16. Shin DM, Donato NJ, Perez-Soler R, et al: Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 7:1204-1213, 2001
17. Cohen EEW, Rosen F, Stadler WM, et al: Phase II study of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21:1980-1987, 2003
18. Clark GM, Perez-Soler R, Siu L, et al: Rash severity is predictive of increased survival with erlotinib HCl. Proc Am Soc Clin Oncol, 22:196, 2003 (abstract 786)
19. Saltz L, Rubin M, Hochster H, et al: Cetuximab (IMC-225) plus irinotecn (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 20:3a, 2001 (abstract 7)
20. Baselga J: Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: Small molecules, big hopes. J Clin Oncol 20:2217-2219, 2002
21. Liu W, Innocenti F, Chen P, et al: Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res 9:1009-1012, 2003
22. Jin W, Xu X. Yang T, et al: p53 mutation, EGFR gene amplification and loss of heterozygosity on chromosome 10, 17 p in human gliomas. Chin Med J (Engl) 113:662-666, 2000
23. Kumar VL, Majumder PK, Kumar V: Observations on EGFR gene amplification and polymorphism in prostatic diseases. Int Urol Nephrol 32:73-75, 2000
24. Gebhardt F, Burger H, Brandt B: Modulation of EGFR gene transcription by secondary structure, a polymorphic repetitive sequence and mutations - a link between genetics and epigenetics. Histol Histopathol 15:929-936, 2000